• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.冷冻电镜结构解析显示,双价 Fab 用作基准标记时,治疗性抗体(favezelimab)与人 LAG3 的结合情况。
Structure. 2023 Oct 5;31(10):1149-1157.e3. doi: 10.1016/j.str.2023.07.013. Epub 2023 Aug 23.
2
Crystal Structure of a Bivalent Antibody Fab Fragment.二价抗体 Fab 片段的晶体结构。
J Mol Biol. 2021 Jan 22;433(2):166714. doi: 10.1016/j.jmb.2020.11.013. Epub 2020 Nov 19.
3
The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.免疫检查点受体 LAG3:结构、功能及癌症免疫治疗的靶点。
J Biol Chem. 2024 May;300(5):107241. doi: 10.1016/j.jbc.2024.107241. Epub 2024 Mar 30.
4
Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3.针对人 LAG3 的治疗性抗体的表位作图。
J Immunol. 2022 Oct 15;209(8):1586-1594. doi: 10.4049/jimmunol.2200309. Epub 2022 Sep 14.
5
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.淋巴细胞激活基因3:慢性淋巴细胞白血病中的一个新治疗靶点。
Haematologica. 2017 May;102(5):874-882. doi: 10.3324/haematol.2016.148965. Epub 2017 Feb 2.
6
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
7
Structural basis for mouse LAG3 interactions with the MHC class II molecule I-A.鼠 LAG3 与 MHC Ⅱ类分子 I-A 相互作用的结构基础。
Nat Commun. 2024 Aug 29;15(1):7513. doi: 10.1038/s41467-024-51930-5.
8
Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryoEM structure determination of membrane proteins.针对 BRIL 的合成抗体作为膜蛋白单颗粒 cryoEM 结构测定的通用基准标记。
Nat Commun. 2020 Mar 27;11(1):1598. doi: 10.1038/s41467-020-15363-0.
9
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.LAG3 外显结构揭示了配体和抗体识别的功能界面。
Nat Immunol. 2022 Jul;23(7):1031-1041. doi: 10.1038/s41590-022-01238-7. Epub 2022 Jun 27.
10
A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.一种新型 LAG3 中和抗体通过双重抑制 MHC-II 和 FGL1 配体结合来改善癌症免疫治疗。
Biomed Pharmacother. 2024 Jun;175:116782. doi: 10.1016/j.biopha.2024.116782. Epub 2024 May 21.

引用本文的文献

1
Phenotypic and targeted drug discovery in immune therapeutics: challenges, opportunities, and future directions.免疫治疗中的表型和靶向药物发现:挑战、机遇与未来方向。
RSC Adv. 2025 Aug 22;15(36):29937-29951. doi: 10.1039/d5ra03914b. eCollection 2025 Aug 18.
2
Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers.利用二价Fab片段作为基准标记物测定的丙型肝炎病毒E2糖蛋白与中和及非中和抗体结合的冷冻电镜结构。
Commun Biol. 2025 May 29;8(1):825. doi: 10.1038/s42003-025-08239-w.
3
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies.针对非小细胞肺癌的免疫检查点抑制剂:超越PD-1/PD-L1单克隆抗体
Cancers (Basel). 2025 Mar 6;17(5):906. doi: 10.3390/cancers17050906.
4
LAG Time in the Era of Immunotherapy-New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3.免疫治疗时代的延迟时间——淋巴细胞激活基因-3免疫抑制机制的新分子见解
Immunol Rev. 2025 Mar;330(1):e70002. doi: 10.1111/imr.70002.
5
Advances in LAG3 cancer immunotherapeutics.LAG3癌症免疫疗法的进展
Trends Cancer. 2025 Jan;11(1):37-48. doi: 10.1016/j.trecan.2024.10.009. Epub 2024 Nov 26.
6
Structural basis for mouse LAG3 interactions with the MHC class II molecule I-A.鼠 LAG3 与 MHC Ⅱ类分子 I-A 相互作用的结构基础。
Nat Commun. 2024 Aug 29;15(1):7513. doi: 10.1038/s41467-024-51930-5.
7
Antigen-binding fragments with improved crystal lattice packing and enhanced conformational flexibility at the elbow region as crystallization chaperones.作为结晶伴侣,具有改善的晶体晶格堆积和增强的肘区构象灵活性的抗原结合片段。
Protein Sci. 2024 Jul;33(7):e5081. doi: 10.1002/pro.5081.
8
Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity.前沿:LAG3 二聚化是 TCR/CD3 相互作用和抑制抗肿瘤免疫所必需的。
J Immunol. 2024 Jul 1;213(1):7-13. doi: 10.4049/jimmunol.2300673.

本文引用的文献

1
Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3.针对人 LAG3 的治疗性抗体的表位作图。
J Immunol. 2022 Oct 15;209(8):1586-1594. doi: 10.4049/jimmunol.2200309. Epub 2022 Sep 14.
2
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.单独使用或联合使用纳武利尤单抗时 LAG-3 阻断抗体 relatlimab 的临床前特征
Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. doi: 10.1158/2326-6066.CIR-22-0057.
3
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.LAG3 外显结构揭示了配体和抗体识别的功能界面。
Nat Immunol. 2022 Jul;23(7):1031-1041. doi: 10.1038/s41590-022-01238-7. Epub 2022 Jun 27.
4
Clinical landscape of LAG-3-targeted therapy.LAG-3靶向治疗的临床概况。
Immunooncol Technol. 2022 Mar 17;14:100079. doi: 10.1016/j.iotech.2022.100079. eCollection 2022 Jun.
5
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.LAG3 在癌症治疗中的分子途径和机制。
Clin Cancer Res. 2022 Dec 1;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390.
6
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
7
Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.开发一种通用的纳米抗体结合 Fab 模块,用于有基准辅助的膜蛋白冷冻电镜研究。
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47). doi: 10.1073/pnas.2115435118.
8
Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies).利用纳米抗体结合支架(Legobodies)进行小蛋白的冷冻电镜结构测定。
Proc Natl Acad Sci U S A. 2021 Oct 12;118(41). doi: 10.1073/pnas.2115001118.
9
Crystal Structure of a Bivalent Antibody Fab Fragment.二价抗体 Fab 片段的晶体结构。
J Mol Biol. 2021 Jan 22;433(2):166714. doi: 10.1016/j.jmb.2020.11.013. Epub 2020 Nov 19.
10
Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor.HLA Ⅱ类分子与 LAG-3 共抑制受体的结合的分子特征。
Eur J Immunol. 2021 Feb;51(2):331-341. doi: 10.1002/eji.202048753. Epub 2020 Oct 9.

冷冻电镜结构解析显示,双价 Fab 用作基准标记时,治疗性抗体(favezelimab)与人 LAG3 的结合情况。

CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.

机构信息

W.M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA; Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.

Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD 21201, USA; Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Rockville, MD 20850, USA.

出版信息

Structure. 2023 Oct 5;31(10):1149-1157.e3. doi: 10.1016/j.str.2023.07.013. Epub 2023 Aug 23.

DOI:10.1016/j.str.2023.07.013
PMID:37619561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11197462/
Abstract

Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 antibodies in clinical trials. However, there is no structural information on the epitopes recognized by these antibodies. We determined the single-particle cryoEM structure of a therapeutic antibody (favezelimab) bound to LAG3 to 3.5 Å resolution, revealing that favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand. The small size of the complex between the conventional (monovalent) Fab of favezelimab and LAG3 (∼100 kDa) presented a challenge for cryoEM. Accordingly, we engineered a bivalent version of Fab favezelimab that doubled the size of the Fab-LAG3 complex and conferred a highly identifiable shape to the complex that facilitated particle selection and orientation for image processing. This study establishes bivalent Fabs as new fiducial markers for cryoEM analysis of small proteins.

摘要

淋巴细胞激活基因 3 蛋白(LAG3)是一种抑制性受体,在肿瘤中耗竭的 T 细胞上上调。LAG3 是癌症免疫治疗的一个主要靶点,许多抗 LAG3 抗体正在临床试验中进行研究。然而,这些抗体所识别的表位还没有结构信息。我们测定了与 LAG3 结合的治疗性抗体(favezelimab)的单颗粒 cryoEM 结构,分辨率为 3.5Å,揭示了 favezelimab 靶向 MHC 类 II 的 LAG3 结合位点,这是其典型配体。favezelimab 的常规(单价)Fab 与 LAG3(~100kDa)之间的复合物体积较小,这对 cryoEM 提出了挑战。因此,我们设计了一种双价 Fab favezelimab,使 Fab-LAG3 复合物的大小增加了一倍,并赋予复合物一个高度可识别的形状,这有助于颗粒的选择和定向,便于图像处理。这项研究确立了双价 Fab 作为 cryoEM 分析小蛋白的新基准标记物。